MediciNova is preparing for regulatory discussions regarding its MN-166 compound, which is part of the COMBAT-ALS Phase 2/3 trial, and has received a $22 million grant from the NIH.
1 report, 1 independent
Updated Jul 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MediciNova is preparing for regulatory discussions regarding its MN-166 compound, which is part of the COMBAT-ALS Phase 2/3 trial, and has received a $22 million grant from the NIH.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
MediciNova (United States)
company in La Jolla, United States
Nothing else this week.
-
National Institute of Health
medical research institute, Pakistani government body
Nothing else this week.
Related events
- NIH is funding research conducted by the National Cancer Institute (NCI) toward an FDA Investigational New Drug (IND) application.
- Cardiff Oncology and Nerviano Medical Sciences are seeking FDA regulatory review for Phase 3 trials and managing a licensing dispute over onvansertib.
- FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Coverage
Newest first; wire copies grouped- GlobeNewswireMediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials MN-166 COMBAT ALS trial down to single digit required enrollment while MN-001 hypertriglyceridemia trial